To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects

• Status: Active, not recruiting
• Trial end date: 2021-11-15
• Target enrollment: 0
• Participant gender: All

Summary

The study is a single-center，randomized, doubled-blinded, placebo-controlled, Only for SHR2285 Phase I trial. This study intends to enroll 52 healthy subjects, regardless of gender. The subjects are divided into three groups: A, B, and C, with 16 cases in each of groups A and B, and 20 cases in group C.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.
• Treatments: Aspirin; Clopidogrel; Ticagrelor

Criteria

Inclusion Criteria:

1. Healthy subjects, aged 18-55 (including boundary);

2. Body mass index (BMI) between 19 to 28 kg/m2 (including boundary), male body weight ≥50 kg and <90 kg , female body weight ≥45kg and <90kg;

3. Participant with no clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters，etc.

4. Understand the study procedures and methods, voluntary to participate in the study and signed the informed consent.

Exclusion Criteria:

1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin/direct bilirubin > 1.2 fold ULN during screening/baseline.

2. Serum creatinine> ULN during screening/baseline.

3. Positive faecal occult blood

4. Abnormal coagulation function.

5. A clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs.

6. Subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening.

7. Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before administration.

8. Human immunodeficiency virus antibody, syphilis serological examination, hepatitis b virus surface antigen, hepatitis c virus antibody were positive.

9. 3 months prior to screening involved in any drug or medical device clinical studies. .

10. Female subjects who did not receive contraception at least 30 days before administration and etc.